SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (334)1/23/2005 4:13:29 PM
From: DewDiligence_on_SI  Read Replies (1) of 671
 
>>All eyes are on Alnylam I suspect.<<

The private firm, Acuity Pharma, will likely have the first test case for an RNAi therapeutic, and it will be in the indication that is best tailored for this approach: age-related macular degeneration (AMD). I’ll be looking to get into ALNY (assuming the price is right) if there are some compelling data from Acuity.

Talk biotech at www.tinyurl.com/zaqn
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News